ADAR1 Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ADAR1 Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8M	Buy	49,000 +30,800	+169%	+$1.69M	0.13%	129
2026 Q1	$1.03M	Buy	18,200 +5,300	+41%	+$309K	0.06%	158
2025 Q4	$767K	Buy	12,900 +8,000	+163%	+$436K	0.06%	156
2025 Q3	$265K	Hold	4,900	–	–	0.02%	169
2025 Q2	$269K	Hold	4,900	–	–	0.04%	143
2025 Q1	$346K	Buy	+4,900	New	+$330K	0.06%	122
2024 Q4	–	Sell	-1,200	Closed	-$80.4K	–	231
2024 Q3	$84.3K	Buy	+1,200	New	+$100K	0.01%	194

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

ADAR1 Capital Management's BMRN Position: Q2 2026 in Review

ADAR1 Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 169% in Q2 2026, buying an estimated $1.69M and bringing the position to 49,000 shares worth $2.8M. The position accounts for 0.13% of the portfolio, ranked #129.

ADAR1 Capital Management first reported a position in BMRN in Q3 2024 and has held it in 7 quarters since. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

ADAR1 Capital Management held 49,000 shares of BioMarin Pharmaceuticals worth $2.8M as of Q2 2026.
ADAR1 Capital Management bought 30,800 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.69M.
BioMarin Pharmaceuticals made up 0.13% of ADAR1 Capital Management's portfolio in Q2 2026, its #129 holding.
ADAR1 Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.